Related Experiment Video
Updated: Aug 12, 2026
08:48
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
COVID-19 and antiphospholipid antibodies
Ayesha Butt1, Doruk Erkan2, Alfred Ian Lee1
1Section of Hematology, Department of Medicine, Yale School of Medicine, 333 Cedar St., New Haven, CT, 06520, USA.
Best Practice & Research. Clinical Haematology
|December 9, 2022
Summary
COVID-19 coagulopathy mirrors antiphospholipid syndrome, involving immunothrombosis and common antiphospholipid antibody production. The clinical impact of these antibodies in COVID-19 remains uncertain, necessitating further research.
Area of Science:
- Immunology
- Hematology
- Infectious Diseases
Background:
- COVID-19 coagulopathy and antiphospholipid syndrome share pathophysiologic features like endotheliopathy and hypercoagulability.
- Antiphospholipid antibody production is common in COVID-19 patients, with varying prevalence reported.
- The clinical significance of these antibodies in COVID-19 is unclear due to transient presence and conflicting study outcomes.
Purpose of the Study:
- To explore the biology of antiphospholipid antibodies in COVID-19 and infections.
- To discuss thrombogenesis mechanisms in antiphospholipid syndrome and compare them to COVID-19 coagulopathy.
- To review the safety of COVID-19 vaccination in patients with antiphospholipid antibodies and syndrome.
Main Methods:
- Literature review focusing on immunothrombosis, antiphospholipid antibodies, and COVID-19.
- Comparative analysis of pathophysiologic mechanisms between antiphospholipid syndrome and COVID-19.
- Synthesis of existing data on COVID-19 vaccination safety in affected patients.
Main Results:
- Shared mechanisms of immunothrombosis observed in both conditions.
- Prevalence of antiphospholipid antibodies in COVID-19 is significant but their clinical impact is debated.
- Data on COVID-19 vaccination safety in antiphospholipid syndrome patients is being compiled.
Conclusions:
- COVID-19 and antiphospholipid syndrome exhibit overlapping immunothrombotic pathways.
- Further research is needed to clarify the role and clinical significance of antiphospholipid antibodies in COVID-19.
- Understanding these parallels may inform management strategies and vaccination protocols.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...